<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00977249</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCTnumber 2008-006426-24</org_study_id>
    <nct_id>NCT00977249</nct_id>
  </id_info>
  <brief_title>Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users</brief_title>
  <official_title>Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users. A Double Blind, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary aim: Will varenicline be better than placebo to get long-term users of NRT to stop?

      Secondary aim: To assess in details some side effects of varenicline i.e. nausea and abnormal
      dreams.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100-200 long-term users of NRT will be enrolled in a placebo, controlled, randomized trial
      with varenicline or placebo for 12 weeks to stop the use of NRT.

      Assessments consist of carbon monoxide in expired air, p-cotinine, body-weight, questions
      about craving, nausea and dreams. Primary result is percent not using NRT and not smoking at
      12 weeks (point prevalence last 7 days) and secondary result is not smoking and not using NRT
      at 12 months. Secondary aims, is a more detailed assessment of nausea and dreams; well-known
      side effects of varenicline and secondary results are a qualitative description of nausea and
      dreams.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary result is percent not using NRT and not smoking at 12 weeks (point prevalence last 7 days) verified by self-declaration combined with a CO &lt; 8 ppm and a p-cotinine &lt; 15 ng/ml</measure>
    <time_frame>12 weeks +/- 1 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>is not smoking and not using NRT at 12 months (point prevalence last 7 days) verified by self-declaration combined with a CO &lt; 8 ppm and a p-cotinine &lt; 15 ng/ml</measure>
    <time_frame>12 months +/- 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Tobacco Dependence</condition>
  <arm_group>
    <arm_group_label>varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Varenicline for 12 weeks.
The treatment schedule for varenicline is:
Varenicline tablets, 0.5 mg x 1 daily, day 1-3 Varenicline 0.5 mg x 2, day 4-6 Varenicline 1 mg x 2, day 7 up to 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>support and visits</intervention_name>
    <description>visits at weeks 0,2,4,6,9 and 12 and 12 months</description>
    <arm_group_label>varenicline</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline</intervention_name>
    <arm_group_label>varenicline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Long-term, daily NRT users (except nicotine patch) (&gt;11 months) ex-smokers that are
             willing to try to stop the use of NRT and adhere to this protocol.

          -  More than 4 pieces of nicotine gum/ sublingual tablets/ lozenges/ per day, OR more
             than 3 inhaler cylinders per day, OR

          -  more than 10 puffs of nasal spray per day.

        Exclusion Criteria:

          -  Age &lt; 18 years,

          -  CO Smokers,

          -  Pregnant and lactating women,

          -  Used varenicline before,

          -  Not able to cooperate,

          -  Other significant diseases that might influence the trial (such as moderate -severe
             cardiac disease, lung cancer,) in expired air &gt; 7 ppm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Tønnesen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gentofte Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip Tønnesen, M.D:</last_name>
    <phone>+4539773508</phone>
    <email>philipt@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helle Johnson, reg. nurse</last_name>
    <phone>+4539773512</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>Hellerup</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helle Johnson, reg Nures</last_name>
      <phone>+4539773512</phone>
    </contact>
    <contact_backup>
      <last_name>Helle Johnson, reg.nures</last_name>
    </contact_backup>
    <investigator>
      <last_name>Philip Tønnesen, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2009</study_first_submitted>
  <study_first_submitted_qc>September 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2009</study_first_posted>
  <last_update_submitted>September 14, 2009</last_update_submitted>
  <last_update_submitted_qc>September 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chief Physician Philip Tønnesen, M.D.</name_title>
    <organization>Gentofte University Hospital</organization>
  </responsible_party>
  <keyword>long term nicotine gum use</keyword>
  <keyword>varenicline</keyword>
  <keyword>adverse effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

